New Drug Evaluations

New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. The primary audiences are primary care healthcare professionals in Northern and Yorkshire such as General Practitioners, Prescribing Advisers, Community/Primary Care Pharmacists and Nurse Prescribers. They are also found to be useful by hospital practitioners and Drug and Therapeutics Committees.

New Drug Evaluations should be read in conjunction with the relevant Summary of Product Characteristics (SPC) and the BNF. Due to the time limited nature of New Drug Evaluations they are published with the expectation that they will not be routinely scheduled for review (see process manual). In view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature after 18 months beyond the publication date of each NDE (indicated in red).

Agents which have been reviewed by the National Institute for Health and Clinical Excellence (NICE) are indicated by the presence of a (N) after the drug name. Please refer to the NICE website to access guidance for these agents.

This information is produced for use by NHS healthcare professionals. See site disclaimer.

NICE Accredited NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is  valid  for 5 years from
7 March 2017.
For more information visit www.nice.org/accreditation

New documents are restricted to stakeholders only for a period of 3 months following publication:

NDE No 153 - Aviptadil/phentolamine for erectile dysfunction - July 2017
NDE No 152 - Fast-acting insulin aspart for the treatment of diabetes mellitus - July 2017

NDE No 151 - Opicapone for mid-to-late stage Parkinson's disease - Apr 2017

 

Document BNF Chapter No.sort descending Published
Varenicline (update) (N) 4.10 Drugs used in substance dependence 81 Jan 08
Zoledronic acid 6.6 Drugs affecting bone metabolism 86 Jan 08
Paliperidone 4.2 Drugs used in psychosis and related disorders 87 Feb 08
Aliskiren 2.5 Hypertension and heart failure 88 Feb 08
Vildagliptin (N) 6.1 Drugs used in diabetes 89 Mar 08
Colesevelam 2.12 Lipid regulating drugs 90 Jul 08
Melatonin 4.1 Hypnotics and anxiolytics 91 Sep 08
Fesoterodine 7.4 Drugs for genito-urinary disorders 92 Sep 08
Methylnaltrexone 1.6 Laxatives 93 Oct 08
Ranolazine (N) 2.6 Nitrates, calcium-channel blockers, and potassium-channel activators 94 Feb 09
Liraglutide (N) 6.1 Drugs used in diabetes 96 Oct 09
Ulipristal 7.3 Contraceptives 97 Oct 09
Qlaira 7.3 Contraceptives 98 Nov 09
Agomelatine 4.3 Antidepressant drugs 99 Dec 09
Intranasal Fentanyl 4.7 Analgesics 100 Dec 09
Febuxostat (N) 10.1 Drugs used in rheumatic diseases and gout 101 Jan 10
Saxagliptin 6.1 Drugs used in diabetes 102 Jan 10
Dronedarone (N) 2.3 Anti-arrhythmic drugs 103 Mar 10
Tredaptive (drug withdrawn from UK market) 104 Mar 10
Denosumab (N) 6.6 Drugs affecting bone metabolism 105 Jun 10
Indacaterol 3.1 Bronchodilators 106 Jul 10
Prucalopride (N) 1.6 Laxatives 107 Sep 10
Combodart 7.4 Drugs for genito-urinary disorders 108 Nov 10
Ticagrelor (N) 2.9 Antiplatelet drugs 109 Jan 11
Fingolimod (N) 8.2 Drugs affecting the immune response 110 May 11
Dabigatran (amended) (N) 2.8 Anticoagulants and protamine 111 Oct 11
Exenatide once-weekly 6.1 Drugs used in diabetes 112 Nov 11
Rivaroxaban in AF (N) 2.8 Anticoagulants and protamine 113 Jan 12
Rivaroxaban for DVT (N) 2.8 Anticoagulants and protamine 114 Feb 12
Linagliptin 6.1 Drugs used in diabetes 115 Mar 12
Asenapine 4.2 Drugs used in psychosis and related disorders 116 Mar 12
Aclidinium Bromide 3.1 Bronchodilators 117 Oct 12
Dapoxetine 7.4 Drugs for genito-urinary disorders 118 Oct 12
Glycopyrronium 3.1 Bronchodilators 119 Nov 12
Racecadotril 1.4 Acute diarrhoea 120 Nov 12
Dapagliflozin (N) 6.1 Drugs used in diabetes 121 Dec 12
Apixaban (N) 2.8 Anticoagulants and protamine 122 Dec 12
Mirabegron (N) 7.4 Drugs for genito-urinary disorders 123 Feb 13
Rivaroxaban for PE (N) 2.8 Anticoagulants and protamine 124 Mar 13
Linaclotide 1.6 Laxatives 125 Mar 13
Tadalafil for BPH 7.4 Drugs for genito-urinary disorders 126 Apr 13
Loxapine Inhalation Powder 4.2 Drugs used in psychosis and related disorders 127 Jun 13
Nalmefene (N) 4.10 Drugs used in substance dependence 128 Aug 13
Rivaroxaban in ACS (N) (replaced by NDE 136) 129 Sep 13
Indacaterol+glycopyrronium (replaced by NDE 137) 130 Dec 13
Fluticasone furoate + Vilanterol 3.2 Corticosteroids 131 Jan 14
Lubiprostone (N) 1.6 Laxatives 132 Mar 14
Canagliflozin (N) 6.1 Drugs used in diabetes 133 Mar 14
Brimonidine for the treatment of facial erythema of rosacea 13.6 Acne and rosacea 134 Jun 14
Lidocaine/prilocaine spray - (replaced by NDE 145) 7.4 Drugs for genito-urinary disorders 135 Jul 14
Rivaroxaban in ACS - update (N) 2.8 Anticoagulants and protamine 136 Oct 14
Indacaterol + glycopyrronium - update 3.1 Bronchodilators 137 Dec 14
Tiotropium for asthma 3.1 Bronchodilators 138 Feb 15
Aclidinium + formoterol 3.1 Bronchodilators 139 Mar 15
Naloxegol for opioid-induced constipation (N) 1.6 Laxatives 140 Apr 15
Insulin degludec and liraglutide 6.1 Drugs used in diabetes 141 May 15
Edoxaban in AF (N) 2.8 Anticoagulants and protamine 142 Jul 15
Naltrexone + bupropion for obesity 4.5 Drugs used in treatment of obesity 143 Sep 15
Liraglutide for the treatment of obesity 4.5 Drugs used in treatment of obesity 144 Oct 15
Lidocaine/prilocaine spray - update 7.4 Drugs for genito-urinary disorders 145 Oct 15
Ivermectin for the treatment of rosacea 13.6 Acne and rosacea 146 Oct 15
Idarucizumab for dabigatran reversal 2.8 Anticoagulants and protamine 147 Dec 15
Guanfacine extended release for ADHD 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder 148 Feb 16
Brivaracetam for focal onset seizures 4.8 Antiepileptics 149 May 16
Lesinurad for the treatment of gout 10.1 Drugs used in rheumatic diseases and gout 150 Jul 16